| Identification | Back Directory | [Name]
PROTOPANAXTRIOL | [CAS]
34080-08-5 | [Synonyms]
g-PPT
20(S)-APPT
PROTOPANAXTRIOL
S-Protopanaxatriol
PROTOPANAXADIOL(RG)
Protopanaxtriol ,98%
20(S)-Protopanaxtriol
(2S)-Protopanaxatriol
Protopanaxatriol, 20S-
20(S)-Protopanaxtriol(PPT)
(20S)-Protopanaxatriol, >98%
20(S)-Protopanaxatriol 34080-08-5
(20S)-Protopanaxatriol (~91% HPLC)
(3b,6a,12b)-Dammar-24-ene-3,6,12,20-tetrol
(20S)-5α-Dammar-24-ene-3β,6α,12β,20-tetrol
Dammar-24-ene-3,6,12,20-tetrol, (3β,6α,12β)-
Dammar-24-ene-3,6,12,20-tetrol, (3beta,6alpha,12beta)- | [Molecular Formula]
C30H52O4 | [MDL Number]
MFCD01861517 | [MOL File]
34080-08-5.mol | [Molecular Weight]
476.74 |
| Chemical Properties | Back Directory | [Melting point ]
242-244 °C | [Boiling point ]
590.0±50.0 °C(Predicted) | [density ]
1.079 | [storage temp. ]
-20°C Freezer | [solubility ]
Chloroform (Slightly), DMSO (Slightly), Methanol (Slightly) | [form ]
Solid | [pka]
14.73±0.70(Predicted) | [color ]
Off-White | [InChIKey]
SHCBCKBYTHZQGZ-NSMZZYIQNA-N | [LogP]
5.890 (est) |
| Hazard Information | Back Directory | [Chemical Properties]
White crystalline powder, soluble in organic solvents such as methanol, ethanol, and DMSO, derived from ginseng. | [Uses]
(20S)-Protopanaxatriol acts as an inhibitor in the production of corticosteroids in fasciculata cells. Used in the clinical treatment of heart diseases. | [Definition]
ChEBI: Protopanaxatriol is a tetracyclic triterpenoid sapogenin (isolated from ginseng and notoginseng) that is that is dammarane which is substituted by hydroxy groups at the 3beta, 6alpha, 12beta and 20 pro-S positions and in which a double bond has been introduced at the 24-25 position. It has a role as a metabolite. It is a tetracyclic triterpenoid, a sapogenin, a 3beta-hydroxy steroid, a 12beta-hydroxy steroid, a 6alpha-hydroxy steroid and a 3beta-hydroxy-4,4-dimethylsteroid. It derives from a hydride of a dammarane. | [Biological Activity]
A metabolites of ginsenosideprotopanaxatriol (g-PPT)could modulate endothelial cell functions through the glucocorticoid receptor (GR) and oestrogen receptor (ER). | [in vivo]
(20S)-Protopanaxatriol (10?mg/kg; i.p.; daily for four weeks) synergizes with Gefitinib to inhibit xenograft growth[3].
(20S)-Protopanaxatriol (50-100 mg/kg; p.o.; 25 days; female BALB/c nude mice bearing breast cancer MCF-7 cell) inhibits the growth of MCF-7 breast cancer cells in a nude mice xenograft assay[4]. | Animal Model: | H1975 murine xenograft tumor model | | Dosage: | 10?mg/kg | | Administration: | I.p.; daily for four weeks | | Result: | The combined g-PPT and Gefitinib (50 mg/kg/day) treatment clearly reduced p-EGFR and KI67 expression and increased c-Caspase3 expression compared to Gefitinib or g-PPT treatment alone.
|
| [target]
Antifection | Glucocorticoid receptor | Oestrogen receptor | LXRα |
|
|